Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.13975 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Fatemeh Chalabianloo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Methadone, Opioid-Related Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Western Health Region, Norway, Norwegian Research Council, Helse Vest Regionalt Helseføretak.
Abstract (Originalsprache)
Background
A considerable inter‐individual variability has been reported in the relationship between methadone doses applied and serum concentrations achieved in methadone maintenance treatment. However, the underlying causes for this variability are not fully understood.
Objectives
We investigated the influence of genetic, pathophysiological and pharmacological factors on serum methadone concentration‐to‐dose ratio (CDR) and discussed the clinical implications of the findings.
Methods
We used data from two retrospective laboratory databases and a prospective cohort study to investigate the impact on methadone CDR of hepatic cytochrome P450 enzyme system (CYP) genetic polymorphisms, age, sex, concomitant medication, liver fibrosis and body mass index through linear mixed model analyses.
Findings
A positive association was found between CDR and the homozygous CYP2B6*6 genotype, concurrent treatment with CYP3A4 inhibitors and body mass index. CDR was lower among women and during concomitant use of CYP inducers. CDR was not associated with age or the degree of liver fibrosis in our investigations.
Conclusions
This research work supports the need for individually tailored dosage considering the various factors that influence methadone CDR. The gained knowledge can contribute to reducing the risks associated with the treatment and optimizing the desired outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
- Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
- Department of Forensic Medicine, Oslo University Hospital, Oslo, Norway.
- Center for psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
- Norwegian Center for Addiction Research, University of Oslo, Oslo, Norway.
- Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.
ORCID-Profile: Fatemeh Chalabianloo, Lars Thore Fadnes, Kjell Arne Johansson, Gudrun Høiseth
Förderung
- Western Health Region, Norway
- Norwegian Research Council
- Helse Vest Regionalt Helseføretak
- Norges Forskningsråd
Zitieren
APA
Chalabianloo, F., Fadnes, L. T., Johansson, K. A., Høiseth, G., Vold, J. H., Kringen, M. K., Spigset, O., & Bramness, J. G. (2024). Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13975
Vancouver
Chalabianloo F, Fadnes LT, Johansson KA, Høiseth G, Vold JH, Kringen MK, et al. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.13975
BibTeX
@article{Chalabianloo2024,
author = {Chalabianloo, Fatemeh and Fadnes, Lars Thore and Johansson, Kjell Arne and Høiseth, Gudrun and Vold, Jørn Henrik and Kringen, Marianne K and Spigset, Olav and Bramness, Jørgen G},
title = {Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.13975}
}
EUVIMED